Get the Stockscreener App
1.13
0.00%
0.00
After Hours:
1.18
0.05
+4.42%
Pyxis Oncology Inc stock is traded at $1.13, with a volume of 174.23K.
It is up +0.00% in the last 24 hours and down -3.42% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.13
Open:
$1.13
24h Volume:
174.23K
Relative Volume:
0.32
Market Cap:
$70.00M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.6141
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
-5.04%
1M Performance:
-3.42%
6M Performance:
-26.14%
1Y Performance:
-67.53%
1-Day Range:
$1.1278
$1.19
1-Week Range:
$1.12
$1.23
52-Week Range:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.13 | 73.72M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
What drives Pyxis Oncology Inc. stock priceFree Stock Movement Tracking - Autocar Professional
What analysts say about Pyxis Oncology Inc. stockPowerful market insights - jammulinksnews.com
Is Pyxis Oncology Inc. a good long term investmentSuperior risk-adjusted returns - Autocar Professional
Pyxis Oncology Inc. Stock Analysis and ForecastExplosive market performance - jammulinksnews.com
Financial Review: Ainos (NASDAQ:AIMD) vs. Pyxis Oncology (NASDAQ:PYXS) - Defense World
what makes pyxis oncology inc. stock price move sharplyGrowth Optimized Stock Radar - Newser
Why Pyxis Oncology Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser
How Pyxis Oncology Inc. stock performs during market volatilityDaily Trade Opportunity - Newser
What makes Pyxis Oncology Inc. stock price move sharplyFree Access to Stock Community - Newser
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Average Price Target from Analysts - Defense World
Pyxis Oncology (NASDAQ:PYXS) Stock Price Up 3.6% – Time to Buy? - Defense World
Pyxis Oncology Appoints New Principal Financial Officer - The Globe and Mail
Pyxis Oncology announces retirement of CFO and COO Pamela Connealy By Investing.com - Investing.com South Africa
Pyxis Oncology, Inc. Announces CFO Changes, Effective July 1, 2025 - MarketScreener
Pyxis Oncology announces retirement of CFO and COO Pamela Connealy - Investing.com
Pyxis Oncology's Equity Incentives: A Strategic Gambit for Clinical Success? - AInvest
Pyxis Oncology, Inc.(NasdaqGS: PYXS) dropped from Russell 3000 Index - MarketScreener
Pyxis Oncology, Inc.(NasdaqGS: PYXS) dropped from Russell 2000 Index - MarketScreener
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Pyxis Oncology Inc (PYXS) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Pyxis Oncology shareholders elect three directors at annual meeting - Investing.com
Pyxis Oncology Elects New Directors at Annual Meeting - TipRanks
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ameriprise Financial Inc. Takes $35,000 Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Jane Street Group LLC Grows Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Nuveen Asset Management LLC Cuts Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Sold by Deutsche Bank AG - Defense World
ProShare Advisors LLC Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Northern Trust Corp Sells 15,449 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments - TipRanks
Millennium Management LLC Has $4.65 Million Stock Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):